Evaluation of [Main Substance] in Combination with Other Agents for Patients with BRAF V600E Mutated Colorectal Cancer

The primary objective of the study titled "New Beacon" is to evaluate the efficacy of a treatment in patients with **BRAF V600E mutated colorectal cancer**. This mutation is associated with a poor prognosis and resistance to standard therapies, making it clinically significant to explore new therapeutic options. The study aims to provide insights into potential improvements in treatment outcomes for this specific genetic mutation in colorectal cancer.

The clinical trial involves participants diagnosed with **BRAF V600E mutated colorectal cancer**. The study population includes both male and female subjects, with an age range spanning from young adults to older adults. The trial does not specifically target a vulnerable population. However, the total number of participants has not been disclosed, as the sponsor has not provided this information. Participants were selected based on their diagnosis, and no specific lifestyle considerations such as diet or physical activity have been highlighted. The trial does not focus on any particular health status beyond the specified medical condition.

The clinical trial is designed to evaluate the efficacy and safety of an investigational treatment for **BRAF V600E mutated colorectal cancer**. This study is a Phase 4 trial, indicating it is conducted after the treatment has been approved for public use, with the aim of gathering additional information on the drug's effect in a larger population. The trial is structured as a randomized, double-blind, controlled study to ensure the reliability and validity of the results. The estimated recruitment start date was February 1, 2021, and the trial is expected to conclude by January 1, 2027, providing a comprehensive evaluation period.

Participants will undergo a series of study visits, beginning with an inclusion visit, also known as the screening visit, to determine eligibility based on predefined criteria. Following successful screening, participants will be randomly assigned to either the treatment group or the control group. Throughout the trial, participants will attend regular follow-up visits to monitor their health status, assess treatment efficacy, and record any adverse events. These visits are crucial for maintaining the integrity of the trial and ensuring participant safety. The study will culminate in an end-of-study visit, where final assessments will be conducted, and participants will be debriefed on the study outcomes.

The expected length of participant involvement will vary depending on individual response to the treatment and adherence to the study protocol. Participants may be withdrawn from the study early if they experience significant adverse effects, fail to comply with study procedures, or if the study is terminated for any reason. The trial's design and procedures are meticulously planned to ensure the collection of high-quality data while prioritizing participant safety and well-being.

In this clinical trial, the experimental medication and non-experimental treatments have not been specified in the provided data. Therefore, a detailed description of the **experimental medication**, including its name, pharmaceutical form, dosage, route, and frequency of administration, cannot be provided. Similarly, information regarding any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, is not available.

Due to the absence of specific details, additional relevant information about drug administration, dosing schedules, and participant compliance monitoring cannot be included. The data does not contain any information about the **disease** being studied or the main objective of the trial. Consequently, a comprehensive description of the treatments used in this clinical trial cannot be constructed based on the current dataset.

The clinical trial is categorized as a Phase 4 study, with an estimated recruitment start date of February 1, 2021, and an estimated end date of January 1, 2027. The trial's efficacy will be assessed through parameters that are not explicitly detailed in the provided data. As such, specific endpoints, methods, and schedules for measuring, collecting, and analyzing efficacy parameters are not available. The trial's focus on efficacy assessment will likely involve standard practices for Phase 4 studies, which typically include post-marketing surveillance to evaluate the long-term effectiveness and safety of the intervention. However, without specific endpoints or tools mentioned, further details on the efficacy assessment cannot be provided.